Ozlem Ozgur Gursoy¹, Ceren Yildiz Eren¹*, Hulusi Goktug Gurer¹ and Ozge Godek²

¹Eskisehir Acibadem Hospital, Obstetrics and Gynecology Clinic, Eskisehir, Turkey
²Eskişehir Acıbadem Hospital Endocrinology Clinic, Eskisehir, Turkey

*Corresponding Author: Ceren Yildiz Eren, Eskisehir Acibadem Hospital, Obstetrics and Gynecology Clinic, Eskisehir, Turkey.

Received: June 24, 2022; Published: July 07, 2022

Abstract

Background: Nowadays, the use of anticoagulants during pregnancy has increased It is used nearly in all of the advanced maternal age and multifetal pregnancies. It is important to study the effects of this increasingly popular treatment modality on other diseases. The purpose of this study is to research the effect of the usage of anticoagulants on the prevalence of gestational diabetes.

Material and Methods: Our study is retrospective. The participants consist of a group of pregnant women. Pregnant women using anticoagulants formed the case, and randomly selected pregnant women not using anticoagulants formed the control group. The study consisted of 800 participants, 400 case and 400 control. The descriptive statistics are age, number of pregnancies and body mass index. A Chi-Square test was performed to study the effect of the usage of anticoagulants on gestational diabetes.

Results: Other than the body mass index of the groups, other descriptive statistics are similar There was no relationship between the participants with and without gestational diabetes in the case group in terms of gestational age, number of pregnancies and body mass index (p > 0.05). In the control group, statistically significant relationship was found (p < 0.01). A statistically significant relationship was found between the case and control groups in terms of gestational diabetes frequency (p < 0.01).

Conclusions: Our study is one of the first studies to research the effect of anticoagulants had on the development of gestational diabetes. The findings of our study show that the usage of anticoagulants decrease the gestational diabetes development rate.

Keywords: Pregnancy; Anticoagulant Drugs; Gestational Diabetes; Low Molecular Weight Heparin; Acetylsalicylic Acid

References

1. Alsheef MA., et al. “Pregnancy and Venous Thromboembolism: Risk Factors, Trends, Management, and Mortality”. Biomed Research International (2020): 4071892.
2. Lameijer H., et al. “Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review”. Thrombosis Research 169 (2018): 123-127.
3. Pankiewicz K., et al. “Non-obstetric complications in preeclampsia”. Prz menopauzalny = Menopause Review2 (2019): 99-109.
4. Zhang W., et al. “Risk scores, prevention, and treatment of maternal venous thromboembolism”. World Journal of Clinical Cases11 (2020): 2210-2218.
5. Beyer-Westendorf J., et al. “Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study”. Lancet Haematology12 (2020): e884-891.
6. McIntyre HD., et al. “Gestational diabetes mellitus”. Nature Reviews Disease Primers 1 (2019): 47.
7. Abu-Heija AT., et al. “Effects of maternal age, parity and pre-pregnancy body mass index on the glucose challenge test and gestational diabetes mellitus”. Journal of Taibah University Medical Sciences4 (2017): 338-342.
8. Kautzky-Willer A., et al. “[Gestational diabetes mellitus (Update 2019)]”. Wien Klin Wochenschr 131 (2019): 91-102.
9. Türkiye Halk Sağlığı Kurumu [Turkish Public Health Institution]. Türkiye Diyabet Programı [Turkey Diabetes Program]. Ankara: T.C. Sağlık Bakanlığı [Turkish Ministry of Health] (2014): 16.
10. Türkiye Nüfus ve Vatandaşlık İşleri Genel Müdürlüğü [General Directorate of Population and Citizenship Affairs of Turkey]. Doğum İstatistikleri [Birth Statistics], 2020. Ankara: Türkiye İstatistik Kurumu [Turkish Statistical Institute] (2021).
11. Türkiye İstatistik Kurumu [Turkish Statistical Institute]. Türkiye Sağlık Araştırması [Turkey Health Survey] 2019. Ankara: Türkiye İstatistik Kurumu [Turkish Statistical Institute] (2020).
12. Dudenhausen JW., et al. “The relationship between maternal age, body mass index, and the rate of preterm birth”. Journal of the Turkish-German Gynecological Association 4 (2018): 182-186.
13. Johnson W., et al. “How Has the Age-Related Process of Overweight or Obesity Development Changed over Time? Co-ordinated Analyses of Individual Participant Data from Five United Kingdom Birth Cohorts”. PLoS Medicine5 (2015): e1001828.
14. Subiabre M., et al. “Insulin therapy and its consequences for the mother, foetus, and newborn in gestational diabetes mellitus”. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease9 (2018): 2949-2956.
15. Sobrevia L., et al. “Insulin Is a Key Modulator of Fetoplacental Endothelium Metabolic Disturbances in Gestational Diabetes Mellitus”. Frontiers in Physiology 7 (2016): 119.
16. Bartakova V., et al. “Serum carboxymethyl-lysine, a dominant advanced glycation end product, is increased in women with gestational diabetes mellitus”. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia1 (2016): 70-75.
17. Xie J., et al. “Cellular signalling of the receptor for advanced glycation end products (RAGE)”. Cell Signal11 (2011): 2185-2197.
18. Li S and Yang H. “Relationship between advanced glycation end products and gestational diabetes mellitus”. Journal of Maternal-Fetal and Neonatal Medicine 17 (2019): 2783-2789.
19. Shi Y., et al. “Low molecular weight heparin (nadroparin) improves placental permeability in rats with gestational diabetes mellitus via reduction of tight junction factors”. Molecular Medicine Reports2 (2020): 623-630.
20. Takeuchi A., et al. “Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells”. Cancer Science6 (2013): 740-749.
21. Dai S., et al. “Therapeutic effect of ursolic acid on fetal development in pregnant rats with gestational diabetes mellitus via AGEs-RAGE signaling pathway”. Journal of Food Biochemistry4 (2021): e13651.
22. Seo DY., et al. “Ursolic acid in health and disease”. Korean Journal of Physiology and Pharmacology3 (2018): 235-248.
23. Villa PM., et al. “Acetylsalicylic acid and prevention of preeclampsia”. Duodecim 3 (2014): 243-250.
24. Dutta S., et al. “Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential Association with Circulating Extracellular Vesicles during Pregnancy”. International Journal of Molecular Sciences 18 (2019): 4370.

Citation

Citation: Ceren Yildiz Eren., et al. “Use of Anticoagulants During Pregnancy Prevent Gestational Diabetes?". Acta Scientific Women's Health 4.8 (2022): 02-07.

Copyright

Copyright: © 2022 Ceren Yildiz Eren., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.